openPR Logo
Press release

Four Key Reasons to Attend SMi's 2019 Biosimilars Conference

08-21-2019 04:48 PM CET | Health & Medicine

Press release from: SMi Group

Biosimilar, Biobetters, biologic, generic drug, immunogenicity, innovator, interchangeability, pharmacist, doctors, dosage

Biosimilar, Biobetters, biologic, generic drug, immunogenicity, innovator, interchangeability, pharmacist, doctors, dosage

SMi Reports: Conference chair, Michel Mikhail, gives four key reasons to attend the Biosimilars conference this September

The 10th Annual Biosimilars conference is set to take place on 25th and 26th September in London, UK.

Conference chair, Michel Mikhail, International Expert in Regulatory Affairs, Global Expert Biosimilars, invites prospective delegates to join the conference and hear from prominent speakers and key opinion leaders within the biosimilars industry to share their experiences and evaluate regulatory framework.

Here are four key reasons to attend this year’s Biosimilars Conference:

1. Take an international look at the regulatory environment of biosimilars
Including the ‘understanding the regulatory framework for biosimilar approval’ section on day-one of the conference and a post-Brexit panel discussion on day-two.

2. Discuss interchangeability of biosimilars in the US through an interactive pre-conference workshop and the main agenda
Including Rodeina Challand’s presentation ‘Barriers Behind the Development and Uptake of Biosimilars in the US’ and Michel Mikhail’s workshop.

3. Benchmark against real world data through case studies and success stories
Including:
• ‘Biosimilars: Reframing Communications and Changing Behaviours’ by Christian Agboton, Senior Global Brand Medical Director, Takeda Pharmaceuticals International GmbH
• ‘Drug Delivery Systems for Biosimilars – Copy or Innovate’ by Sebastien Maag, Device Project Leader, Novartis – Sandoz GmbH
• ‘Using SPOT and SLIM Technology and Upstream Process Modulation to Reduce Cost of Goods of Biosimilars’ by Louis Boon, CSO, Bioceros BV
• ‘Case Study: The First Monoclonal Antibody Manufactured with a Fully Continuous Biomanufacturing Process that Enters Phase I Studies’ by Jaap Wieling, Chief Development Officer, BiosanaPharma BV

4. Access biosimilars patent challenges and how they have overcome in industry
Including the ‘overcoming legal issues with patent protection section of the conference on day-two.

The brochure with the two-day conference agenda, half-day workshops and expert speaker line-up is available to download online at http://www.biosimilars-europe.com/pr5

This year’s conference will kick-off on Tuesday 24th September with two pre-conference half-day workshops: one on “US-FDA Interchangeability Guideline”, in the morning and, the other on “Advancing Biosimilars Development and Uptake in MENA & GCC Region” in the afternoon.

For those interested in attending, there in an exclusive ‘special managers offer at £999’ available for conference bookings made before 31st August. Registrations can be made online at http://www.biosimilars-europe.com/pr5

For sponsorship or exhibitor enquiries, please contact Alia Malick on +44 (0)20 7827 6168 or amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or ssapal@smi-online.co.uk

Biosimilars 2019
25th – 26th September 2019
London, UK
http://www.biosimilars-europe.com/pr5
#SMiBiosimilars

45 Curlew Street
London, SE1 2ND
Simi Sapal

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Four Key Reasons to Attend SMi's 2019 Biosimilars Conference here

News-ID: 1824549 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for Biosimilar

Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." Get
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of